R-GemOx方案和R-GDP方案二线治疗复发难治性弥漫大B细胞淋巴瘤的临床比较观察  

Clinical comparative study of R-GemOx regimenand R-GDP regimenas second-line regimens for patients with relapsed or refractory diffuse large B-cell lymphoma

作　　者：赵蓉爽 张明智[1] ZHAO Rongshuang;ZHANG Mingzhi(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052

出　　处：《肿瘤基础与临床》2021年第3期203-207,共5页journal of basic and clinical oncology

基　　金：国家自然科学基金资助项目(81970184)。

摘　　要：目的对比利妥昔单抗联合奥沙利铂和吉西他滨(R-GemOx)和利妥昔单抗联合吉西他滨、顺铂、地塞米松(R-GDP)二线方案治疗复发难治性弥漫大B细胞淋巴瘤(R/R-DLBCL)的疗效及不良反应。方法回顾性分析2010年5月至2019年3月郑州大学第一附属医院肿瘤科收治的R/R-DLBCL患者93例,按治疗方案分为R-GemOx组和R-GDP组,比较分析2组患者的临床病理特征、近期疗效及不良反应。结果93例患者可评价疗效。R-GemOx组总有效率为59.57%、临床获益率为74.47%,R-GDP组分别为52.17%、78.26%,比较差异均无统计学意义(χ^(2)=0.517,P=0.472;χ^(2)=0.185,P=0.667)。2组不良反应均主要为血液学毒性,其中R-GemOx组消化道反应发生率为51.06%,明显低于R-GDP组的71.74%,差异有统计学意义(χ^(2)=4.189,P=0.041)。结论R-GemOx和R-GDP均为R/R-DLBCL患者有效的二线治疗方案。从不良反应来看,R-GemOx的消化道反应少于R-GDP,对于年龄较大、体质较差的患者可推荐使用R-GemOx方案。Objective To compare theefficacy and side effects of oxaliplatin and gemcitabine combined with rituximab(R-GemOx)regimenand gemcitabine,cisplatin,dexamethasone combined with rituximab(R-GDP)regimen as second-line regimens forpatients with relapsed or refractory diffuse large B-cell lymphoma(R/R-DLBCL).Methods The clinical data of 93 patients withR/R-DLBCL admitted in Department of Oncology of the First Affiliated Hospital of Zhengzhou University from May 2010 to March 2019 were retrospectively analyzed.All the patients were assigned into two groups according to their chemotherapy regimens:the R-GemOx group and the R-GDP group.The clinical characteristics,short-term efficacy and side effects were compared between these two groups.Results The 93 patients can be evaluated for curative effect.The total response rate and the clinical benefit rate were respectively 59.57%and 74.47%in the R-GemOx group,and were respectively 52.17%and 78.26%in the R-GDP group(χ^(2)=0.517,P=0.472;χ^(2)=0.185,P=0.667).The main side effects of the two groups were hematological toxicity.The gastrointestinal reaction rate in the R-GemOx group was significantly less than that in the R-GDP group(51.06%and 71.74%;χ^(2)=4.189,P=0.041).Conclusion Both the R-GemOx regimen and the R-GDP regimen are effective second-line treatments for patients with R/R-DLBCL.In terms of adverse reactions,the R-GemOx regimen has less gastrointestinal reactions than the R-GDP regimen.For the older,poorer R/R-DLBCL patients,the R-GemOx regimen can be recommended.

关 键 词：复发难治性弥漫大B细胞淋巴瘤 R-GemOx方案 R-GDP方案 

分 类 号：R733.1[医药卫生—肿瘤]